By the PharmaTradz BD Team. Published October 2026.
API manufacturers in China and India are two of the most important sources of active pharmaceutical ingredients (APIs) for generic medicines, and in practice they complement each other more than they compete. China is especially strong upstream, in key starting materials, intermediates, fermentation products and many finished APIs. India is strong in APIs and in turning them into finished medicines, and it buys much of its upstream material in China. Neither country is the right answer for every molecule: the sensible choice depends on the product, the market you file in, the documents the site holds and how much supply risk you can carry.
Two different roles in one supply chain
A medicine's chemistry runs in stages. A key starting material (KSM) is the building block from which the regulated API process begins. Intermediates are the part-made molecules along the route. The API is the active substance itself, and the finished dosage form (FDF) is the tablet, capsule or injection the patient takes.
China has deep capacity in basic and fine chemicals and in fermentation, the large-scale microbial process behind many antibiotics, vitamins and amino acids. That depth lets many Chinese sites make a molecule all the way from commodity chemicals, and it also supports a broad CDMO (contract development and manufacturing) sector serving drug developers worldwide.
India has a deep base of API manufacturers, many of them part of groups that also make finished medicines for regulated and emerging markets. Its dependence on China upstream is documented in official figures. In a Rajya Sabha reply on 10 March 2026, India's government reported imports of APIs, KSMs and drug intermediates worth ₹36,124 crore in 2024-25, of which ₹27,032 crore, about three-quarters, came from China.
To build domestic capacity, India's Cabinet approved a Production Linked Incentive (PLI) scheme for critical KSMs, drug intermediates and APIs on 21 March 2020, with an outlay of ₹6,940 crore. It now covers 41 products. The first approvals in January 2021 targeted fermentation products such as penicillin G, 7-ACA, erythromycin thiocyanate and clavulanic acid, for which India was then fully dependent on imports. By December 2025, 38 projects covering 28 products had been commissioned, according to the same March 2026 reply.
China and India at a glance
| Factor | China | India |
|---|---|---|
| Typical strength | KSMs, intermediates, fermentation products, many APIs; CDMO services | APIs and finished dosage forms, often within integrated groups |
| Upstream position | Broad domestic chemical and fermentation base | About three-quarters of API, KSM and intermediate imports by value came from China in 2024-25; PLI scheme adding local capacity |
| National regulator | NMPA; ICH regulatory member; PIC/S applicant since November 2023 | CDSCO; ICH observer; revised Schedule M GMP rules notified December 2023 |
| US FDA presence | Share of API sites for US products rose 2.5% between 2020 and 2025 | Share of API sites for US products rose 3.3% between 2020 and 2025 |
| EU import paperwork | CEP or ASMF, plus written confirmation from the exporting authority | CEP or ASMF, plus written confirmation from the exporting authority |
| Planning points | Lunar New Year slowdown; records may need translation for audits | Festival-season slowdowns; records usually kept in English |
Regulatory track record
Both countries supply APIs into the strictest markets, and both have sites with strong and weak inspection histories. The useful unit of judgement is the site, not the country.
For the United States, the FDA's FY2025 Report on the State of Pharmaceutical Quality, published in mid-2026, found that between 2020 and 2025 the share of API manufacturing locations for US application products rose by 2.5% for China and 3.3% for India, while the US and European shares fell. The US and Europe still hold the largest shares of API and FDF sites respectively. The FDA has run an unannounced inspection pilot covering drug makers in India and China, and on 6 May 2025 it announced wider use of unannounced inspections at foreign sites.
For Europe, sites in both countries hold many Certificates of Suitability (CEPs) from the EDQM, which also inspects CEP holders. Under the EU's Falsified Medicines Directive, every API imported into the EU since 2 July 2013 must come with a written confirmation from the exporting country's authority that the site meets GMP equivalent to EU standards. Neither China nor India is on the EU's list of countries exempt from this.
For donor-funded markets, WHO has prequalified APIs made at sites in both countries, for example for HIV medicines. China's NMPA is an ICH regulatory member and has held PIC/S applicant status since November 2023. India's CDSCO is an ICH observer, and India's revised Schedule M GMP rules, notified on 28 December 2023, gave firms below a set turnover until 31 December 2025 to comply after an extension.
Documentation: DMF, CEP and ASMF
Whichever country you buy in, the API file decides how fast you can register. For the US, ask for a Type II Drug Master File (DMF) and a Letter of Authorization. For Europe, ask for a CEP or an Active Substance Master File (ASMF), whose restricted part goes only to the regulator. For other markets, ask for the CTD Module 3.2.S package. Our guide to CEP, DMF and ASMF explains which one you need. Check that the file names the same site, route and salt form you are buying.
Quality systems and inspection access
Both countries apply the international GMP standard for APIs, ICH Q7. Differences show up in practice. Ask whether the site has hosted FDA, EU or WHO inspectors recently and what the outcome was. Plan audits early: visas, travel and translation of batch records take time, and a remote audit is a useful screen but not a full substitute. Check data integrity closely, including audit trails and raw data, wherever the site is.
Cost and lead time drivers
Price differences rarely come down to country alone. The main drivers are backward integration (whether the site makes its own KSM), scale, solvent and energy prices, environmental compliance costs, currency movements and the cost of keeping DMFs and CEPs current. Lead time depends on campaign scheduling, KSM availability, holiday shutdowns and freight route. Our articles on API price trends and China dependency and low-cost APIs sourced in China look at pricing in more detail.
Trade and policy factors
US tariffs. Proclamation 11020 of 2 April 2026, issued under Section 232, imposes a 100% tariff on certain patented pharmaceuticals and their ingredients, with lower rates for some trading partners and for companies with approved agreements. Generic medicines and their ingredients are not covered at present, but the Commerce Department must report within a year on whether action on generics may be needed. Other duties may apply depending on tariff classification, so check with your customs broker.
BIOSECURE Act. Enacted on 18 December 2025 as section 851 of the FY2026 National Defense Authorization Act, it restricts US federal agencies from buying biotechnology equipment or services from designated "biotechnology companies of concern", and from contracting with firms that use them in performing federal contracts. The government's first list is due by 18 December 2026, and the prohibitions start only after federal procurement rules are revised. Our BIOSECURE Act explainer covers the detail.
US resilience policy. An executive order of 5 May 2025 directed the FDA to strengthen its risk-based foreign inspections. Executive Order 14336 of 13 August 2025 asked for a six-month reserve of APIs for about 26 critical drugs, preferring domestic supply.
EU resilience policy. The proposed Critical Medicines Act (March 2025) reached a provisional deal between the Council and Parliament on 12 May 2026 and was awaiting formal adoption at the time of writing. It would ask public buyers to apply resilience criteria, such as diversified supply, in tenders for critical medicines.
Worked example: pricing a second source
A distributor buys 2,000 kg a year of an API from one site at USD 80 per kg. A second site quotes USD 92 per kg with a CEP and a US DMF. Moving 30% of volume to the second site costs 600 kg × USD 12 = USD 7,200 a year extra. Against that, a single failed batch or a three-month stoppage at the first site could cost far more in lost tenders. The buyer also checks that the two sites do not buy their KSM from the same maker; if they do, the second source protects the API step but not the step upstream.
What buyers should check: a dual-sourcing checklist
Map the chain. Ask each supplier where its KSMs and key intermediates are made. True diversification means different upstream sources, not just two API sites.
Compare the routes. A different synthesis route can change the impurity profile, residual solvents (ICH Q3C), mutagenic impurities (ICH M7), nitrosamine risk, polymorph and particle size. Ask for three recent batch analyses and the full specification.
Qualify the site. Review inspection history, warning letters and EU non-compliance reports, then audit and sign a quality agreement that covers change notification.
Prove it in your product. Make drug product batches with the new API and put them on stability.
File the change. In the US, an alternative API source for an approved generic is normally a prior approval supplement. In the EU, under the revised variations framework that applies from 15 January 2026, a new source covered by a CEP can usually be added by a Type IA notification, while an ASMF route usually needs more data and review. Run it all through your change control system.
Our global API sourcing guide for 2026 adds wider supplier validation steps.
How PharmaTradz can help
Tell us the molecule, volume and markets you file in, and whether you need a DMF, CEP or ASMF. Our API suppliers service matches you with qualified manufacturers in China, India and elsewhere, and shares their document status and upstream sources before you commit. You can send us an RFQ for a primary or second source today. For unfamiliar terms, see our pharma abbreviations A-Z.
Frequently Asked Questions(FAQs)
Is China or India better for API sourcing?
Neither is better overall. China is especially strong in key starting materials, intermediates and fermentation products, while India is strong in APIs and finished medicines; the right choice depends on the molecule, the site's inspection history and the documents it holds for your market.
Why does India import APIs and KSMs from China?
Many upstream chemicals and fermentation products are made at scale in China. India's government reported that about three-quarters of its imports of APIs, KSMs and drug intermediates by value in 2024-25 came from China, and its PLI scheme for bulk drugs, approved in March 2020, aims to build more domestic capacity.
Do Chinese API manufacturers have US FDA and EU approvals?
Many Chinese and Indian API sites hold US DMFs, have been inspected by the FDA and hold EU Certificates of Suitability. Always check the specific site's DMF status, CEP and recent inspection outcome rather than relying on the country.
Are generic APIs subject to the 2026 US Section 232 pharmaceutical tariffs?
Not at present. Proclamation 11020 of 2 April 2026 applies to certain patented pharmaceuticals and their ingredients, and generic medicines and their ingredients are excluded, although the Commerce Department must report within a year on whether action on generics may be needed.
How do I add a second API supplier to an approved product?
Qualify the new site, compare its impurity profile and physical properties, make product batches and run stability, then file the change. In the US this is normally a prior approval supplement; in the EU the variation type depends on whether the new source is covered by a CEP or an ASMF.
